Table 4.
Number of infusion reactions classified according to grade of seriousness
| Group | Grade of seriousness | Infusion reactions | ||||
| All | Infliximab dosage unchanged | Infliximab dosage increased at 3–6 months | Infliximab dosage increased at 6–12 months | Infliximab dosage increased at 12 months | ||
| RA patients (n = 45) | Life threatening | 2 | 1 | 1 | 0 | 0 |
| Serious | 16 | 11 | 2 | 1 | 2 | |
| Moderate | 24 | 15 | 8 | 5 | 6 | |
| Mild | 3 | 1 | 0 | 1 | 1 | |
| SpA patients (n = 10) | Life threatening | 0 | 0 | 0 | 0 | 0 |
| Serious | 6 | 4 | 1 | 1 | 0 | |
| Moderate | 2 | 1 | 1 | 0 | 0 | |
| Mild | 2 | 1 | 1 | 1 | 0 | |
RA, rheumatoid arthritis; SpA, spondylarthropathy.